Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Q1 2020 Earnings Presentation
14 slides from Marinomed Biotech's earnings presentation, May 26, 2020
Slide 1: Creating innovative therapies for respiratory, allergy and eye diseases
Creating innovative therapies for respiratory, allergy and eye diseases Results Q1 2020 Investor Presentation Vienna, 26th May 2020
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda Marinomed – the future with COVID-19 ▪ COVID-19 – FFG-Funding – Our Project ▪ Marinosolv®: innovation and better products drive the market ▪ Q1 2020 in numbers ▪ Positive Outlook for 2020 3
Slide 4: Carragelose portfolio overview
Carragelose® portfolio overview Six products already on the market, more to be developed 1 Nasal products • Anti-viral nasal spray • Anti-viral kids nasal spray Launched • Anti-viral cold/flu nasal spray 1 • Anti-viral decongestant nasal spray • Anti-viral Carragelose® -Xylometazoline combination La
Slide 5: Marinomed has relevant experience
Marinomed has relevant experience Carragelose® is successfully treating virus related symptoms since 2008 Carragelose® binds Corona viruses (no data for Sars-CoV-2) Post hoc clinical data from 2 double blind placebo controlled trials Group Rhino Corona1 Influenza A 8.8 ± 0.6 9.0 ± 0.7 8.7 ± 1.0 Plac
Slide 6: COVID-19 – FFG Funding – Our Project
COVID-19 – FFG Funding – Our Project Carragelose® – radical innovation for the treatment of viral pneumonia 06/20 10/20 03/21 efficacy, safety, diagnostic local tolerance GLP* and non-GLP* Phase I inhalation POC inhalation viral pneumonia Aim Investment ▪ Inhalation therapy for acute viral ▪ Up to €
Slide 7: Marinomed updated pipeline
Marinomed updated pipeline Total of 6 new programs added to the pipeline respiratory respiratory gastrointestinal respiratory 7
Slide 8: Carragelose segment with solid growth
Carragelose® segment with solid growth Growth path of Carragelose® maintained throughout the year 2019 and beyond Revenue by Quarter (in m€) Comments ▪ Double digit growth in revenues from the sale of products in the Carragelose® segment +35% achieved 1.9 1.7 ▪ Corona season started in March, so ful
Slide 9: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) €m Q1 2020 Q1 2019 1 Revenue €m Q1 2020 Q1 2019 Revenues 1 1.0 0.8 Sale of goods 0.9 0.8 License revenues 0.1 0.0 Other income 0.1 0.2 Other revenues 0.0 0.0 Other net gains/losses (0.0) 0.0 Total revenue 1.0 0.8 Materials expenses (0.7) (0.5) Services expenses 2 (
Slide 10: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m Q12020 2019 1 Acquisition of property in Korneuburg €0.4m (2019: €0.4m) as well as assets under construction €2.3m Assets (2019: €1.8m) Intangible assets 1.7 1.6 Therein Austrian Research Promotion in the amount Property, plant and equipment 1 2.9 2.5
Slide 11: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m Q12020 2019 1 Therein IPO related paid-in capital of €20.3m (net of transaction costs) and conversion of the Equity and liabilities convertible bond in the amount of €13.1m Share capital 1.5 1.5 Capital reserves 2 Primarily related to
Slide 12: Statement of cash flows (IFRS)
Statement of cash flows (IFRS) Change in cash position primarily related to loss for the period Net Cash at Net change in Net D&A Cash at beginning Loss for financial working interest and Investing Financing end of of period the period result capital paid other cash flow cash flow period 12
Slide 13: Positive Outlook 2020
Positive Outlook 2020 Investments in Marinosolv® and commercialisation of Carragelose® COVID-19 boosts demand for virus blocking products ▪ Marinomed’s technology platforms are broadly and excellently positioned ▪ Marinomed is involved in extensive national and international research activities ▪ In
Slide 14: www.marinomed.com
: Orrarino www.marinomed.com